Figure 2 from the PURPOSE-1 trial changed the world.
Between gray and red bars representing the study’s background HIV incidence and the arms randomized to receive oral pre-exposure prophylaxis (PrEP) was white space filled only by a previously unimaginable number: zero. Zero infections over one year among the 2,134 cisgender adolescent girls and young women who received the novel long-acting inje...
The article presents a narrative about the potential impact of lenacapavir on ending the HIV epidemic. However, its implementation is threatened by funding cuts and a high price tag. The proposed solution is subscription pricing, which was previously successful in expanding access to hepatitis C antivirals.
Patterns detected: ARC-0024 Ambiguity (the article does not specify the timeline for lenacapavir's subscription pricing implementation)
Root cause: The narrative reflects tensions between pub...